Once-weekly semaglutide injection from Novo Nordisk, FDA-approved for type 2 diabetes and related heart and kidney risk reduction. Not approved for weight management. Self-pay $349 to $499/month (checked Sept 20, 2026).
FDA-approved for
Boxed warning: Risk of thyroid C-cell tumors (see Prescribing Information). Read the Prescribing Information. This page is not medical advice. Talk to a licensed clinician.
Verified on September 20, 2026. Source: NovoCare Pharmacy (novocare.com). Prices can change, so confirm the final price before you pay.
$199/month for 0.25 mg and 0.5 mg, first 2 monthly fills, for new patients, through Dec 31, 2026 (checked Sept 20, 2026)
As little as $25/month for up to 3 months (maximum $100/month savings; government beneficiaries excluded)
Free (NovoCare Pharmacy)
Lowest standard self-pay price per month from each manufacturer’s own pharmacy. Introductory offers and insurance prices are excluded. Medications, doses and approved uses differ, so this is a price reference, not a treatment comparison.
Ozempic injection is a once-weekly semaglutide medicine from Novo Nordisk. It is FDA-approved, along with diet and exercise, to improve blood sugar in adults with type 2 diabetes, to reduce the risk of major cardiovascular events in adults with type 2 diabetes and known heart disease, and to reduce the risk of kidney disease worsening, kidney failure and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.
Ozempic is not FDA-approved for chronic weight management. Wegovy is the semaglutide product approved for that use. Self-pay prices below were checked on NovoCare Pharmacy on September 20, 2026.